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Abstract 
Background: Gastric cancer (GC) is one of the most malignant tumors and the second leading cause of cancer‑
related deaths in the world. Luteolin, a flavonoid present in many fruits and green plants, suppresses cancer progres‑
sion. The effects of luteolin on GC cells and their underlying mechanisms remain unclear.
Methods: Effects of luteolin on cell proliferation, migration, invasion, and apoptosis were examined in vitro and 
in vivo by cell counting kit‑8 (CCK‑8), transwell assays, and flow cytometry, respectively. Real‑time reverse transcription 
polymerase chain reaction (RT‑PCR) and Western blots were performed to evaluate Notch1 signaling and activation 
of epithelial‑mesenchymal transition (EMT) in GC cells treated with or without luteolin. Immunohistochemistry was 
performed to examine proliferation and Notch1 expression in xenograft tumors.
Results: Luteolin significantly inhibited cell proliferation, invasion, and migration in a dose‑dependent and time‑
dependent manner and promoted cell apoptosis. Luteolin reversed EMT by shrinking the cytoskeleton and by induc‑
ing the expression of epithelial biomarker E‑cadherin and downregulating the mesenchymal biomarkers N‑cadherin, 
vimentin and Snail. Furthermore, Notch1 signaling was inhibited by luteolin, and downregulation of Notch1 had 
similar effects as luteolin treatment on cell proliferation, migration, and apoptosis. In addition, luteolin suppressed 
tumor growth in vivo. A higher expression of Notch1 correlated with a poor overall survival and a poor time to first 
progression. Furthermore, co‑immunoprecipitation analysis revealed that activated Notch1 and β‑catenin formed a 
complex and regulated cell proliferation, migration, and invasion.
Conclusions: In this study, GC progression was inhibited by luteolin through suppressing Notch1 signaling and 
reversing EMT, suggesting that luteolin may serve as an effective anti‑tumor drug in GC treatment.
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Background
The incidence of cancer is higher worldwide due to vari-
ous factors such as smoking, environmental pollution, 
obesity and aging. Gastric cancer is the fourth most 
common cancer and the second leading cause of cancer-
related deaths in the world [1]. It is the leading cause of 
tumor-related deaths among males in China [2]. How-
ever, effective GC treatment is absent and resistance 
to chemotherapy is one of its most crucial obstacles, 
particularly in advanced GC. Due to a lack of validated 
screening programs, most GC patients are diagnosed 
at a late stage, leading to a high mortality, in develop-
ing countries [3, 4]. Therefore, it is necessary to iden-
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design novel drugs for its treatment. Artemisinin, which 
is isolated from a Chinese herb, suppresses tumor devel-
opment by causing cell cycle arrest and inducing apop-
tosis in cancer cells [5, 6]. Luteolin is a flavonoid present 
in many fruits and green plants, and has the ability to 
suppress cancer progression [7, 8], which indicates that it 
may be used as a drug for the treatment of tumors.
Notch signaling is implicated in a majority of cancers 
for promoting the malignant phenotype by inducing cell 
proliferation, metastasis, drug resistance, and inhibiting 
apoptosis [9–12]. Ligand binding to Notch, which is a 
single-pass transmembrane receptor, leads to its cleavage 
and release of the Notch intracellular domain (NICD), 
which translocates to the nucleus and interacts with 
transcription factor RBPJ to regulate cellular functions 
[13–15]. The Wnt/β-catenin pathway is conserved across 
species [16] and regulates tissue development in embryos 
and tissue maintenance in adults. Aberrant activation of 
Wnt/β-catenin promotes the progression of a variety of 
cancers due to uncontrolled cell proliferation and growth 
[17, 18]. There is a crosstalk between the Notch and 
Wnt/β-catenin signaling pathways in many cell types for 
regulating cell proliferation and migration during devel-
opment [19, 20]. However, this crosstalk may cause syn-
ergistic or antagonistic effects depending on the context 
[21, 22], and its status in GC remains unclear.
Epithelial-mesenchymal transition (EMT) is not only a 
physiological process but also a pathological process that 
regulates cell phenotype and functions during embryo-
genesis as well as tumor development [23–25]. Mor-
phological changes due to EMT and effects of the tumor 
microenvironment cause resistance to therapy in many 
cancers through a number of signaling pathways [26–28]. 
Notch signaling-induced EMT is a key factor implicated 
in tumor metastasis [29–31]. Therefore, we addressed the 
relationship between Notch and EMT in GC progression.
In order to identify the mechanisms underlying GC 
development as well as effective treatment methods, we 
studied the therapeutic effect of luteolin on GC and its 
potential molecular mechanisms of action.
Results
Luteolin inhibits the proliferation and colony formation 
ability of GC cells
Hs-746T and MKN28 GC cells were cultured with 0, 
10, 20 and 30 μM luteolin. CCK-8 assay was performed 
every 24 h, and results showed that proliferation of GC 
cells were effectively inhibited by luteolin in a dose- and 
time-dependent manner (Fig.  1a, b). Moreover, luteo-
lin treatment also significantly reduced the number of 
colonies compared with the control group (for Hs-746T, 
P = 0.0097; for MKN28, P = 0.0014; Fig. 1c, d).
Luteolin promotes apoptosis in GC cells
The percentage of early and late apoptosis was increased 
upon treatment with 10 and 30 μM luteolin compared 
with the control group (Fig.  2a, b). The proportion of 
apoptotic Hs-746T (0 vs. 10 μM, P = 0.0047, 0 vs. 30 μM, 
P = 0.0009, Fig. 2c) and MKN28 (0 vs. 10 μM, P = 0.0014, 
0 vs. 30  μM, P  =  0.0010, Fig.  2d) cells increased in a 
dose-dependent manner. Since PI3K/Akt signaling is 
implicated in cell apoptosis in a majority of tumors, we 
examined the phosphorylated Akt levels in GC cells after 
treatment with luteolin. The results showed that phos-
phorylated Akt (Ser-473) was decreased by luteolin treat-
ment (Fig. 2e).
Luteolin inhibits invasion and migration of GC cells
NCI-N87 GC cells showed a mesenchymal phenotype, 
as evidenced by F-actin staining, in the absence of lute-
olin treatment (Fig.  3a). However, when NCI-N87 cells 
were treated with luteolin, the cytoskeleton shrank and 
cell size decreased (Fig. 3b). These findings indicate that 
luteolin can suppress the motility of GC cells. Tran-
swell assays showed that invasion and migration of GC 
cells was significantly inhibited by luteolin treatment 
(P < 0.01, Fig. 3c–f).
Luteolin reverses EMT and suppresses Notch1 signaling 
in GC cells
The remodeling of the cytoskeleton upon luteolin treat-
ment indicated that luteolin may regulate this process by 
inhibition of EMT in GC cells. We observed that the epi-
thelial biomarker E-cadherin was increased and the mes-
enchymal biomarkers N-cadherin, vimentin, and Snail 
were reduced in a dose-dependent manner upon luteo-
lin treatment (Fig. 4b). Luteolin treatment also caused a 
decrease in β-catenin levels (Fig. 4c). We also found that 
Notch1, cyclin-D1, and Hes-1 were downregulated due 
to luteolin treatment (Fig.  4d–f), suggesting that luteo-
lin prevented GC progression by suppressing Notch 
signaling.
Luteolin suppresses GC progression via decreasing Notch1 
expression
To investigate the suppressing effects of luteolin on 
GC progression whether through regulating Notch1 
or not, Notch1 was downregulated or overexpressed in 
GC cells. Notch1 knockdown in Hs-746T and MKN28 
cells decreased the expression of its target genes Hes-
1, Hey-1, and cyclin-D1 (Fig. 5a). Moreover, prolifera-
tion and migration were inhibited in Notch1-silenced 
GC cells compared with the control cells (Fig. 5b, c). In 
addition, Notch1 knockdown promoted cell apoptosis 
and reversed EMT in GC cells (Fig.  5d, e). However, 
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overexpression of Notch1 recovered EMT in Hs-746T 
following luteolin treatment as well as elevated AKT 
phosphorylation (Fig.  5f ). The inhibiting effect on 
cell migration by luteolin treatment was also partially 
reversed by overexpression of Notch1 (Fig. 5g). These 
observations confirm that luteolin treatment sup-
pressed GC progression by inhibiting Notch signaling. 
Furthermore, NICD directly bound with β-catenin to 
form a complex, while the interaction between NICD 
and β-catenin was abrogated subsequent to luteolin 
treatment in  vitro and in  vivo (Fig.  5h). The interac-
tion between NICD and β-catenin may contribute to 
promote cell proliferation, cell migration, and inhibit 
cell apoptosis in GC by regulating downstream target 
genes (Fig. 5i), which is blocked by luteolin treatment.
Luteolin suppresses tumor growth in vivo
To test the effects of luteolin on tumor growth in  vivo, 
MKN28 cells were injected subcutaneously into nude 
mice. After the tumors were formed, nude mice were 
injected 6 times intraperitoneally with PBS or luteolin 
(10 mg/kg). We found that the tumor volume (P < 0.01) 
and tumor weight (P  <  0.05) in luteolin-treated mice 
were less than that in the control group (Fig. 6a–c). Fur-
thermore, β-catenin, Notch1 and Ki-67 expression were 
decreased in tumors from luteolin-treated mice (Fig. 6d); 
while in contrast, TUNEL staining was elevated in 
tumors from mice treated with luteolin (Fig. 6e). Analysis 
of data available online on KMplot indicated that higher 
expression of Notch1 correlated with a poor overall sur-
vival (OS) (P = 0.00022, Fig. 6f ) and a poor time to first 
Fig. 1 Effects of luteolin on proliferation and colony formation ability in GC cells. a The proliferation of Hs‑746T GC cells was inhibited upon luteolin 
treatment compared with the control group. Cell proliferation curves indicated that luteolin suppressed the growth of GC cells in a dose‑ and time‑
dependent manner. The significant inhibited effect on cell growth by luteolin was observed at 4th and 5th day after luteolin treatment. The results 
of 4th and 5th day were compared to that in their control groups using the Student’s t test. There was no statistical significance at 4th day after 
10 μM lueolin treatment compared with 0 μM luteolin, but a statistical significance at 5th day. Both 20 and 30 μM luteolin resulted in a statistical 
significance at 4th and 5th day. b The proliferation of MKN28 GC cells was inhibited upon luteolin treatment compared with the control group. The 
results of 4th and 5th day were compared using the Student’s t test. There was a statistical significance at 4th and 5th day after lueolin treatment 
compared with 0 μM luteolin. c Luteolin significantly reduced the colony formation ability of GC cells. d Number of colonies in control and luteolin‑
treated groups in two GC cell lines. Results are the means of three independent experiments. *P < 0.05, **P < 0.01
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progression (FP) (P = 0.00062, Fig. 6g). These results sug-
gest that luteolin can suppress GC progression by inhib-
iting Notch1 expression.
Based on our observations, we propose a model for the 
roles of luteolin, Notch1, and β-catenin in GC (Fig.  7). 
Ligand binding activates Notch, causing translocation of 
NICD to the nucleus, which forms a complex with acti-
vated β-catenin. This results in the regulation of target 
genes and induces cell proliferation and metastasis in 
GC. The PI3K/Akt signaling enhances the formation of 
this complex. Luteolin can block Notch signaling, and 
exerts an anti-tumorigenic effect in GC by inhibiting cell 
proliferation and migration and increasing cell apoptosis. 
Thus, luteolin may be an effective drug for the treatment 
of cancers.
Discussion
Although tumor resection and chemotherapy contrib-
ute significantly to GC treatment, drug resistance and 
genetic variation reduce their efficacy [32]. A number 
of compounds obtained from Chinese herbs possess 
anti-tumor activities, such as those from Taurine [33], 
Fig. 2 Effect of luteolin on cell apoptosis in GC. a, b The apoptosis of GC cells was increased upon luteolin treatment compared with the control 
groups. The percentages of both early and late apoptotic cells in 10 and 30 μM luteolin‑treated groups were higher than the control groups. c, 
d The histograms show the percentage of cell apoptosis in GC cells. e Phosphorylation of Akt (Ser‑473) was inhibited by luteolin, as observed by 
Western blot analysis. Results are the means of three independent experiments. *P < 0.05, **P < 0.01
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Dioscorea bulbifera [34], and Matrine [35, 36]. Although 
it has been reported that luteolin exerts a marked antitu-
mor effect in cMet-overexpressing patient-derived tumor 
xenograft models of gastric cancer, luteolin by which way 
regulating cancer metastasis remains unclear [37]. Lute-
olin is a flavonoid extracted from Chinese herbs, and in 
this study, we examined its effects on metastasis in GC 
and the underlying mechanisms.
Uncontrolled growth of cells is in the hallmark of 
tumor progression [38]. Hence, we first examined the 
effects of luteolin on cell proliferation and colony forma-
tion in GC, and observed that proliferation of GC cells 
was significantly inhibited by luteolin in a time- and 
dose-dependent manner. Next, we found that apopto-
sis was elevated by luteolin by inhibiting Akt signaling, 
which itself is implicated in cancer metastasis, prolifera-
tion, and apoptosis [39, 40]. We also observed that the 
cytoskeleton of GC cells shrank upon treatment with 
luteolin. F-actin staining was used to confirm the changes 
in the cytoskeleton of GC cells treated with luteolin, and 
the results suggest that luteolin might inhibit GC motility 
by reversing EMT in a manner similar to that observed 
in pancreatic and ovarian cancers [7]. As expected, upon 
luteolin treatment, the epithelial biomarker E-cadherin 
was increased. In the contrast, the mesenchymal bio-
markers N-cadherin, vimentin, and Snail were reduced in 
a dose-dependent manner.
Notch signaling was activated during EMT in cardiac 
development, colorectal cancer, and hepatic carcinoma 
progression [29, 41]. Notch signaling is predicted to be 
the potential target of luteolin by our endogenous tumor 
network model and regulation of Notch signaling plays a 
key role in tumor progression [42, 43]. Hence, we evalu-
ated the effect of luteolin on Notch signaling, and luteo-
lin treatment indeed inhibited Notch signaling. Silencing 
of Notch1 inhibited proliferation and migration, induced 
apoptosis, and reversed EMT of GC cells, which was con-
sistent with the effects observed upon luteolin treatment. 
Fig. 3 Effects of luteolin on cytoskeleton and motility in GC cells. NCI‑N87 GC cells were treated with or without luteolin (30 μM) for 24 h, and 
analyzed by F‑actin staining (Red F‑actin, Blue DAPI, 200×). a Control NCI‑N87 GC cells showed a spindle and fusiform shape, which indicates higher 
motility. b Luteolin treatment (30 μM) for 24 h caused shrinking in NCI‑N87 GC cells and a decrease in the number of pseudopodia on the cell 
surface. c, d The cell motility was assessed by transwell assays (200×). e, f The number of migrating and invading cells is quantified. Results are the 
means of three independent experiments. *P < 0.05, **P < 0.01
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Furthermore, overexpression of Notch1 partially recov-
ered EMT and cell migration, illustrating that luteolin 
suppressed GC progression by inhibiting Notch signaling.
The Notch and Wnt/β-catenin signaling pathways 
interact in many cell types in synergistic or antagonis-
tic ways, depending on the context [20, 22]; however, it 
has not been studied in GC. The interaction between 
β-catenin and NICD was observed in GC cells as well as 
in leukemia and intestinal stem cells [13, 15], suggesting 
that they might form a complex to promote GC progres-
sion by inducing EMT, elevating proliferation, and inhib-
iting apoptosis [16, 44]. Luteolin treatment inhibited 
crosstalk between β-catenin and NICD by decreasing 
their expression. In an in vivo assay, luteolin suppressed 
tumor growth by inhibiting proliferation and inducing 
apoptosis. Luteolin treatment also significantly reduced 
Notch1 expression. Moreover, higher Notch1 expres-
sion was correlated with a poor OS and a poor time to 
FP [45]. We propose a model for the role of Notch1 and 
β-catenin in GC progression (Fig. 7). NICD interacts with 
β-catenin to regulate target genes, causing induction of 
cell proliferation and metastasis and inhibition of apop-
tosis. Luteolin inhibits Notch1 and β-catenin expression, 
thus exhibiting an anti-tumorigenic effect in GC.
Conclusions
In this study, we found that luteolin significantly sup-
pressed GC progression by inhibiting cell proliferation, 
migration, and invasion; inducing apoptosis; and revers-
ing the EMT. Meanwhile, the Akt, β-catenin, and Notch 
signaling pathways were inhibited by luteolin. Further-
more, the effects of downregulation of Notch1 were sim-
ilar to those observed upon treatment of GC cells with 
luteolin. In addition, higher Notch1 expression correlated 
with a poor OS. Luteolin suppressed tumor growth and 
Notch1 signaling in  vivo. Therefore, luteolin may be an 
effective drug for GC treatment.
Methods
Cell culture and materials
The human GC cell lines NCI-N87 and MKN28 were 
maintained in our lab, and Hs-746T was purchased from 
Fig. 4 Effects of luteolin on EMT and Notch signaling in GC cells. a The chemical structure of luteolin. b The protein levels of the EMT markers were 
assessed by Western blot analysis in GC cells treated with different concentrations of luteolin. Luteolin increased E‑cadherin levels and significantly 
decreased N‑cadherin, β‑catenin, vimentin, and Snail levels. c Immunofluorescence analysis showed that β‑catenin was decreased in GC cells upon 
luteolin treatment (Green β‑catenin, Blue DAPI, 200×). d The expression of Notch1, cyclin‑D1, and Hes‑1 was examined by Western blot analysis in 
GC cells after treatment with luteolin. e Gray scale ratio of Notch signaling markers in GC cells. f The mRNA levels of Notch targets were evaluated by 
RT‑PCR. Results are the means of three independent experiments. *P < 0.05, **P < 0.01
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American Type Culture Collection. Cells were cultured at 
37  °C in 5% CO2 and saturation humidity in RPMI-1640 
medium with 10% fetal bovine serum containing penicillin 
and streptomycin. Luteolin was purchased from Aladdin 
Industrial Corporation (Shanghai). The molecular weight 
is 286.24 g/mol and the purity is greater than 98% (HPLC).
Cell proliferation and colony formation assays
Cell proliferation was monitored by Cell Counting Kit-8 
(CCK-8). In brief, GC cells were suspended in medium 
with or without luteolin treatment and then plated in 
96-well plate at the concentration 2000 cells/well. Cell 
proliferation was measured every 24  h for 5  days after 
adding CCK-8 reagent 2  h at the absorbance 450  nm 
using Epoch Microplate Spectrophotometer (Bio Tek). 
For colony formation, Hs-746T and MKN28 cells were 
plated in 6-well plates at the concentration 1000 cells/
well. The experimental groups were treated with luteolin 
for 24 h groups and then replaced for fresh medium. After 
10–14 days, the plates were stained with 1% crystal violet.
Apoptosis assay
Hs-746T and MKN28 cells were plated in 6-well plates 
treated with or without luteolin for 24  h. Then cells 
were collected and examined by apoptosis detection 
kit (BD Pharmingen). Briefly, 3  μl annexin V-FITC and 
Fig. 5 Effects of Notch1 on cell proliferation and EMT in GC cells. a The targets of Notch1 signaling were examined by Western blot assay after 
Notch1 downregulation using a shRNA. b Suppression of Notch1 caused inhibition of proliferation in GC cells. c The migration ability of GC cells 
was reduced in Notch1‑silenced cells. d Suppression of Notch1 induced cell apoptosis. e The expression of E‑cadherin was increased in Notch1 
knocked down GC cells, while in contrast, N‑cadherin, vimentin, and Snail expression levels were decreased. f Overexpression of Notch1 decreased 
E‑cadherin expression following luteolin treatment in Hs‑746T cells, while increased vimentin and pAKT expression. g The inhibiting effect of luteo‑
lin on cell migration was reversed subsequent to Notch1 overexpressing in Hs‑746T cells. h Co‑IP of β‑catenin and NICD in GC cells. The interaction 
between NICD and β‑catenin was abrogated with luteolin treatment in vitro and in vivo. i Proposed molecular model for Notch and β‑catenin cross‑
talk. Results are the means of three independent experiments. *P < 0.05, **P < 0.01
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5 μl propidium iodide were added into cells successively 
for 15  min. And then GC cells were monitored by flow 
cytometry. Right upper quadrant represents percentage 
of late apoptosis. Right lower quadrant represents per-
centage of early apoptosis.
Migration and invasion assays
A number of 1 × 105 GC cells were suspended in serum-
free medium with or without Matrigel (BD Bioscience, 
CA, USA) in upper chambers (Corning Costar, NY, USA) 
and luteolin or PBS were added into 24-well plates. Next, 
Fig. 6 Effect of luteolin on tumor growth in vivo and effect of Notch1 on prognosis. a Images of MKN‑28 xenograft tumors treated with PBS or 
luteolin. b Tumor volumes were measured every week (*P < 0.05, **P < 0.01). c Average weights of xenograft tumors in nude mice (*P < 0.05). d 
Expression of β‑catenin, Notch1, and Ki‑67 in xenograft tumors by IHC (200×). e TUNEL staining of xenograft tumors (200×). f, g Higher expression 
of Notch1 was correlated to a poor overall survival (OS) (P = 0.00022) and poor time to first progression (FP) (P = 0.00062)
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GC cells were fixed by 10% formalin and stained by 0.5% 
crystal violet after 24  h. Finally, GC cells that passed 
through membrane were photographed and counted.
Immunofluorescent staining
Cells were plated into 8-well glass (Merck Millipore) for 
overnight and then fixed, permeated and blocked accord-
ing to protocols. We next stained the cells with β-catenin 
antibody (1:100; Cell Signaling Technology, CST), fol-
lowed by incubation with fluorescent secondary antibody 
for 1  h at room temperature. The nuclei were stained 
with DAPI. And to visualize the cytoskeleton of GC cells, 
rhodamine phalloidin (1:20; CST) was used. Slides were 
analyzed and imaged on a fluorescence microscope.
Vector construction and transfection
Notch1 shRNA, negative control, pCMV-Notch1 
(H3176 pLenti-CMV-MCS-HA-3Flag-P2A-EGFPT2A-
Puro), and control vectors were purchased from Oobio 
Corporation (Shanghai, China) and the vectors carry 
puromycin-resistance function. siRNA sequences 
of Notch1 or negative control (NC) were as follows: 
Notch1, GCAACAGCTCCTTCCACTT; NC, TTCTC-
CGAACGTGTCACGT. Lip2000 (Invitrogen, Carlsbad, 
USA) was used to transfect vectors into GC cells and 
then transfected cells were selected by treatment with 
puromycin. The effects of shRNA and pCMV-Notch1 
were confirmed at protein level using western blot assay.
Western blot assay
The method was consist with the previous [46]. In brief, 
proteins of cells were separated by SDS-PAGE and then 
were transferred into PVDF membranes. Primary anti-
body (1:1000 dilutions) AKT, p-AKT, NICD, β-catenin, 
E-cadherin, N-cadherin, Snail and vimentin were pur-
chased from cell signaling technology (CST, USA). 
Notch-1, Hes-1, Hey-1, Cyclin-D1 (1:1000 dilutions) 
and GAPDH (1:10000 dilutions) were purchased from 
Fig. 7 Proposed mechanisms of Notch and Wnt/β‑catenin signaling in GC progression. When ligands bind to the Notch receptors, activated NICD 
translocates into the nucleus and forms a complex with activated β‑catenin. The complex formation results in the regulation of target genes to 
induce cell proliferation and metastasis and inhibits apoptosis. Luteolin blocks the complex formation and inhibits cell proliferation and metastasis, 
and increases cell apoptosis, suggesting an anti‑tumorigenic effect. Luteolin may be a drug for GC treatment
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Proteintech. After incubation with primary antibody, sec-
ondary antibody followed. Finally, the results were visual-
ized by Tanon system.
Immunoprecipitation experiment
Cells were lysed at 4 °C using RIPA and the followed pro-
cures were based on Co-IP kit (Pierce, Rockford, USA) 
according to manufacturer’s instructions. In brief, a total 
of 300 μg proteins were incubated overnight with specific 
primary antibodies β-catenin and NICD at 4 °C. Immune 
complexes were precipitated with protein A/G Sepharose 
beads and next were examined by western blot.
RT‑PCR assay
RNA was extracted from GC cells treated with luteolin or 
without, and then RNA was reversed to cDNA. Primers 
for Notch-1, forward GCTTGTGGTAGCAAGGAAGC 
(20b), reverse CCACATTCAAGTGGCTGATG (20b); 
Hes-1, forward ACACGACACCGGATAAACCAA 
(21b), reverse CGAGTGCGCACCTCGGTA (18b); Cyc-
lin-D1, forward GGGTGGGTTGGAAATGAACT (20b), 
reverse CTTCCTCTCCAAAATGCCAG (20b). RT-PCR 
was performed using SYBR-green according to manufac-
turer’s instructions.
In vivo experiment and immunohistochemistry
BALB/c male nude mice (Institute of Zoology, China 
Academy of Sciences) were used to evaluate the role of 
luteolin in tumor growth in  vivo. Nude mice received 
humane care and the study protocols were carried out 
according to a protocol approved by the Institutional 
Animal Care and Use Committee (IACUC) at Shanghai 
Jiao Tong University, Shanghai, China. Tumor nodules 
were measured every week, and was calculated using 
formula: tumorous volume =  (width2 ×  length)/2. Mice 
were killed at 4  weeks after injection and then tumors 
were weighed and fixed for immunohistochemistry stain-
ing (IHC).
For IHC, sections staining was performed according to 
the DAKO protocol, using primary antibody (1:200 dilu-
tions) Notch1, β-catenin and Ki-67. The tunel assay was 
performed using In situ cell death detection kit (Roche). 
Blue represents nucleus, green represents death cells.
Statistics
Differences between experimental groups were assessed 
by the Student’s t test or one-way ANOVA. Student’s 
t test was used to examine the statistical differences 
between the two groups. The significant inhibited effect 
on cell growth by luteolin was observed at 4th and 5th 
day after luteolin treatment. The results of 4th and 5th 
day were compared to that in their control groups using 
the Student’s t test in Fig. 1a, as well as in Fig. 1b. Survival 
was analyzed with the Kaplan–Meyer method compar-
ing survival curves by log-rank test. Data are shown as 
mean ± SD. A two-tailed value of P < 0.05 was consid-
ered statistically significant. Statistical analyses were per-
formed using IBM SPSS 19.0 software (SPSS Inc).
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